Analyst Consensus ?
1 unmapped firm rating excluded from the percentages.
Akamai Technologies, Inc. · AKAM · FY2026 Q2 · Calendar Q3 2026
Akamai's supplied Q2 analysis supports a constructive growth case built on AI-driven edge inference, multiyear infrastructure commitments and security demand. The counterweight is that realizing this opportunity depends on capacity expansion, contract conversion and maintaining margins through a more capital-intensive buildout.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Relative to the supplied prior-quarter analysis, Akamai's multiyear commitments increased to more than $2.8 billion, the company added a $600 million four-year GPU services contract, completed the approximately $205 million LayerX acquisition, and planned $500 million of Q3 capex to expand GPU capacity. The supplied analysis also points to a shift from earlier guidance toward accelerated low-teens growth in 2027.
Management's guidance sentiment was raised, with an expectation that revenue growth can accelerate to the low-teens range in 2027; the supplied analysis also indicates sharply higher capex for GPU capacity.
Follow AKAM with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 free1 unmapped firm rating excluded from the percentages.
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Sep 22, 2026. Not an FN2 forecast.
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Citigroup | Neutral | Neutral | Maintain | Sep 4, 2026 |
| Piper Sandler | Overweight | Neutral | Upgrade | Sep 1, 2026 |
| JP Morgan | Neutral | Underweight | Upgrade | Aug 13, 2026 |
| Susquehanna | Positive | Positive | Maintain | Aug 10, 2026 |
| HSBC | Hold | Buy | Downgrade | Aug 10, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 7, 2026 |
| TD Cowen | Hold | Hold | Maintain | Aug 7, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Aug 7, 2026 |
| Guggenheim | Buy | Buy | Maintain | Aug 7, 2026 |
| Baird | Neutral | Neutral | Maintain | Aug 7, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 27, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | May 14, 2026 |
| B of A Securities | Buy | Neutral | Upgrade | May 13, 2026 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | May 8, 2026 |
| Keybanc | Overweight | Overweight | Maintain | May 8, 2026 |
| DA Davidson | Buy | Buy | Maintain | Feb 13, 2026 |
| Raymond James | Outperform | Outperform | Maintain | Aug 8, 2025 |
| Needham | Hold | Hold | Maintain | Feb 21, 2025 |
| Oppenheimer | Outperform | Perform | Upgrade | Dec 2, 2024 |
| Tigress Financial | Strong Buy | Strong Buy | Maintain | Aug 29, 2024 |
| Craig-Hallum | Buy | Hold | Upgrade | Aug 9, 2024 |
| CFRA | Hold | Hold | Maintain | May 24, 2023 |
| Loop Capital | Hold | Hold | Maintain | Mar 1, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 15, 2023 |
| Truist Securities | Buy | Buy | Maintain | Aug 10, 2022 |
| FBN Securities | Outperform | Outperform | Maintain | Aug 10, 2022 |
| Credit Suisse | Neutral | Neutral | Maintain | Feb 10, 2021 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Jul 29, 2020 |
| B. Riley Securities | Buy | Buy | Maintain | Apr 29, 2020 |
| B. Riley FBR | Buy | Buy | Maintain | Apr 29, 2020 |
| Nomura Instinet | Neutral | Neutral | Maintain | Apr 15, 2020 |
| Nomura | Neutral | Neutral | Maintain | Apr 15, 2020 |
| Goldman Sachs | Neutral | Sell | Upgrade | Mar 26, 2020 |
| B. Riley | Buy | Buy | Maintain | Feb 12, 2020 |
| Deutsche Bank | Sell | Hold | Downgrade | Mar 25, 2019 |
| MKM Partners | Buy | Buy | Maintain | Jun 27, 2018 |
| Wells Fargo | Market Perform | Market Perform | Maintain | Oct 25, 2017 |
| Drexel Hamilton | Buy | Buy | Maintain | Mar 21, 2017 |
| FBR Capital | Market Perform | Underperform | Upgrade | Oct 26, 2016 |
| Pacific Crest | Overweight | Downgrade | Jul 27, 2016 | |
| Stifel Nicolaus | Hold | Hold | Maintain | Mar 24, 2016 |
| Macquarie | Neutral | Neutral | Maintain | Nov 3, 2015 |
| Canaccord Genuity | Hold | Hold | Maintain | Oct 28, 2015 |
| JMP Securities | Market Outperform | Market Perform | Upgrade | Aug 28, 2015 |
| Jefferies | Hold | Hold | Maintain | May 2, 2014 |
| Maxim Group | Buy | Buy | Maintain | Mar 15, 2013 |
| Janney Montgomery Scott | Neutral | Buy | Downgrade | Feb 7, 2013 |
| Janney Capital | Neutral | Buy | Downgrade | Feb 7, 2013 |
| Oxen Group | Hold | Hold | Maintain | Mar 14, 2012 |
| Stifel | Buy | Buy | Maintain | Feb 9, 2012 |
| PiperJaffray | Neutral | Neutral | Maintain | Feb 9, 2012 |
Upside is calculated against the persisted previous close $117.41. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Piper Sandler | Analyst unavailable | $125 | $108.62 | +6.5% | Aug 31, 2026 |
| HSBC | Stephen Bersey | $123 | $110.54 | +4.8% | Aug 10, 2026 |
| Robert W. Baird | Analyst unavailable | $140 | $113.88 | +19.2% | Aug 7, 2026 |
| RBC Capital | Analyst unavailable | $135 | $114.89 | +15.0% | Aug 7, 2026 |
| UBS | Roger Boyd | $125 | $111.79 | +6.5% | Jul 29, 2026 |
| Evercore ISI | Peter Levine | $175 | $113.3 | +49.1% | Jul 27, 2026 |
| Morgan Stanley | Sanjit Singh | $165 | $161.14 | +40.5% | May 14, 2026 |
| Susquehanna | Shyam Patil | $175 | $147.71 | +49.1% | May 11, 2026 |
| Scotiabank | Patrick Colville | $180 | $141.92 | +53.3% | May 8, 2026 |
| UBS | Analyst unavailable | $160 | $141.46 | +36.3% | May 8, 2026 |
| Robert W. Baird | Analyst unavailable | $150 | $140.3 | +27.8% | May 8, 2026 |
| Oppenheimer | Analyst unavailable | $180 | $140.73 | +53.3% | May 8, 2026 |
| D.A. Davidson | Analyst unavailable | $185 | $135.3 | +57.6% | May 8, 2026 |
| Raymond James | Analyst unavailable | $140 | $135.93 | +19.2% | May 8, 2026 |
| Evercore ISI | Analyst unavailable | $165 | $133.5 | +40.5% | May 8, 2026 |
| Craig-Hallum | Analyst unavailable | $190 | $116.69 | +61.8% | May 8, 2026 |
| KeyBanc | Jackson Ader | $195 | $116.69 | +66.1% | May 8, 2026 |
| Raymond James | Frank Louthan | $120 | $105.47 | +2.2% | Mar 12, 2026 |
| Raymond James | Frank Louthan | $100 | $99.02 | -14.8% | Feb 23, 2026 |
| Goldman Sachs | Analyst unavailable | $76 | $94.17 | -35.3% | Feb 23, 2026 |
| Piper Sandler | Analyst unavailable | $97 | $94.17 | -17.4% | Feb 23, 2026 |
| Scotiabank | Patrick Colville | $120 | $99.42 | +2.2% | Feb 20, 2026 |
| Susquehanna | Analyst unavailable | $120 | $98.89 | +2.2% | Feb 20, 2026 |
| Evercore ISI | Analyst unavailable | $115 | $99.26 | -2.1% | Feb 20, 2026 |
| Robert W. Baird | Analyst unavailable | $110 | $109.59 | -6.3% | Feb 20, 2026 |
| UBS | Roger Boyd | $110 | $109.59 | -6.3% | Feb 20, 2026 |
| KeyBanc | Analyst unavailable | $120 | $109.59 | +2.2% | Feb 20, 2026 |
| Morgan Stanley | Sanjit Singh | $120 | $109.59 | +2.2% | Feb 20, 2026 |
| Oppenheimer | Analyst unavailable | $115 | $92.68 | -2.1% | Feb 5, 2026 |
| Morgan Stanley | Analyst unavailable | $115 | $88.12 | -2.1% | Jan 12, 2026 |
| Scotiabank | Analyst unavailable | $105 | $87.36 | -10.6% | Jan 9, 2026 |
| Piper Sandler | James Fish | $89 | $85.1 | -24.2% | Jan 5, 2026 |
| KeyBanc | Jackson Ader | $115 | $85.89 | -2.1% | Dec 15, 2025 |
| Oppenheimer | Analyst unavailable | $100 | $87.17 | -14.8% | Nov 17, 2025 |
| Piper Sandler | James Fish | $83 | $70.53 | -29.3% | Aug 8, 2025 |
| Morgan Stanley | Analyst unavailable | $85 | $73.65 | -27.6% | Aug 5, 2025 |
| Morgan Stanley | Keith Weiss | $90 | $73.81 | -23.3% | Apr 16, 2025 |
| Robert W. Baird | William Power | $115 | $101.02 | -2.1% | Nov 11, 2024 |
| HSBC | Stephen Bersey | $121 | $101.02 | +3.1% | Nov 11, 2024 |
| Scotiabank | Patrick Colville | $115 | $91.57 | -2.1% | Aug 9, 2024 |
| Craig-Hallum | Jeff Van Rhee | $125 | $91.57 | +6.5% | Aug 9, 2024 |
| RBC Capital | Mark Mahaney | $100 | $91.57 | -14.8% | Aug 9, 2024 |
| Guggenheim | Raymond McDonough | $128 | $96.97 | +9.0% | Jul 29, 2024 |
| HSBC | Stephen Bersey | $96 | $96.37 | -18.2% | Jul 24, 2024 |
| Piper Sandler | James Fish | $112 | $95.14 | -4.6% | Jul 15, 2024 |
| Scotiabank | Patrick Colville | $110 | $92.22 | -6.3% | Jul 8, 2024 |
| Susquehanna | Shyam Patil | $135 | $92.86 | +15.0% | May 10, 2024 |
| Piper Sandler | James Fish | $114 | $94.39 | -2.9% | May 10, 2024 |
| KeyBanc | Thomas Blakey | $119 | $94.48 | +1.4% | May 10, 2024 |
| D.A. Davidson | Rudy Kessinger | $125 | $101.44 | +6.5% | May 7, 2024 |
| Piper Sandler | James Fish | $136 | $105.82 | +15.8% | Apr 9, 2024 |
| Robert W. Baird | William Power | $135 | $110.16 | +15.0% | Mar 7, 2024 |
| Guggenheim | Ramond McDonnough | $75 | $78.66 | -36.1% | Feb 16, 2023 |
| Loop Capital Markets | Analyst unavailable | $91 | $87.49 | -22.5% | Feb 7, 2023 |
| Morgan Stanley | Keith Weiss | $102 | $95.81 | -13.1% | Aug 10, 2022 |
| Truist Financial | Analyst unavailable | $125 | $95.98 | +6.5% | Aug 10, 2022 |
| Morgan Stanley | Analyst unavailable | $102 | $92.26 | -13.1% | Aug 10, 2022 |
| RBC Capital | Analyst unavailable | $110 | $95.08 | -6.3% | Aug 10, 2022 |
| Morgan Stanley | Analyst unavailable | $110 | $90.65 | -6.3% | Jul 11, 2022 |
| Piper Sandler | Analyst unavailable | $102 | $93.13 | -13.1% | Jul 6, 2022 |
| Morgan Stanley | Analyst unavailable | $118 | $100.74 | +0.5% | May 4, 2022 |
| Piper Sandler | James Fish | $126 | $116.7 | +7.3% | Apr 25, 2022 |
| Tigress Financial | Ivan Feinseth | $168 | $109.94 | +43.1% | Jan 26, 2022 |
| KeyBanc | Thomas Blakey | $140 | $112.08 | +19.2% | Jan 18, 2022 |
| Morgan Stanley | Keith Weiss | $130 | $110.87 | +10.7% | Nov 3, 2021 |
| Truist Financial | Gregory P Miller | $140 | $105.13 | +19.2% | Nov 2, 2021 |
Track every rating change on AKAM the moment it posts. Free to start.
Start freeAkamai Technologies, Inc. (AKAM) is a leading global provider of cloud services, specializing in the secure delivery, optimization, and protection of online content and business applications across the internet. The company's primary focus involves offering sophisticated cloud-based solutions designed to shield digital infrastructure, websites, applications (including APIs), and end-users from a wide array of cyberattacks and online threats, all while simultaneously enhancing performance. Akamai further excels in accelerating web and mobile experiences, facilitating dynamic and highly responsive websites and applications.…
| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ADBE Adobe Inc. | FY2026 Q3 · Calendar Q3 2026 | +0.8% | +1.4% | Adobe raises FY26 outlook as AI strategy broadens |
| ORCL Oracle Corporation | FY2027 Q1 · Calendar Q3 2026 | +10.3% | -1.7% | Oracle raises FY27 outlook as AI demand accelerates cloud growth |
| SAIL SailPoint, Inc. | FY2027 Q2 · Calendar Q3 2026 | +13.8% | -1.2% | SailPoint pairs 25% ARR growth with accelerating AI-driven adoption |
| CIEN Ciena Corporation | FY2026 Q3 · Calendar Q3 2026 | +22.0% | -10.4% | Ciena raises outlook as AI networking demand lifts backlog |
| DOCU DocuSign, Inc. | FY2027 Q2 · Calendar Q3 2026 | +6.4% | +3.7% | DocuSign Q2 FY27: IAM momentum supports a raised outlook |
| IOT Samsara Inc. | FY2027 Q2 · Calendar Q3 2026 | +25.0% | +3.7% | Samsara: AI adoption expands as FY27 guidance holds |
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.